Coronavirus vaccine prices have been revealed or leaked for some of the companies at the forefront of COVID-19 vaccine research. Some pharmaceutical firms are looking to make a profit off of COVID-19 vaccines in the coming years. If the drugs are approved, they could cost anywhere between $20 to $40 per dose, with some therapies …
A second coronavirus vaccine trial has entered the final stage of testing, and the research could be finalized as soon as October. One of the BioNTech/Pfizer vaccine candidates that were studied in preclinical and Phase 1/2 clinical trials has advanced to Phase 2/3. it will be tested on 30,000 participants at 120 sites around the …
The latest coronavirus vaccine development update comes from the US government, which inked a new deal for a promising vaccine made by BioNTech and Pfizer. The government pledged nearly $2 billion to secure 100 million doses of the experimental drug, assuming the vaccine candidate clears the final stage of clinical trials and receives the required …
Another coronavirus vaccine candidate has shown promising results in a Phase 1/2 trial conducted in the US. An mRNA experimental drug made by BioNTech, which partnered with Pfizer for the development of the drug, proved it can deliver the neutralizing antibodies that would be able to block the coronavirus and prevent infection. According to the …
Another potential coronavirus vaccine might be available this fall. Pfizer said the candidate it’s developing with BioNTech could be ready by October if everything goes well. There’s no guarantee that any of these vaccines will work, and several logistic challenges have to be addressed before mass immunization campaigns can be conducted. The development of vaccines …
German biopharmaceutical company BioNTech partnered with Pfizer on the development of an mRNA vaccine for the novel coronavirus. Their product reached the clinical phase trial stage, with Phase 1/2 testing already underway in Germany and the US. The first American volunteers will soon enroll in the trial, and the two companies say they may be …
A new coronavirus vaccine candidate from Germany has entered human trials, and it might be ready for emergency use as soon as this fall. Vaccine candidate BNT162 was administered to volunteers in Germany, although healthy American adults will also be included in the trial. BioNTech is working with Pfizer on the drug that has the …
